Mildronate (Meldonium Dihydrate)

Meldonium Dihydrate, the active ingredient in Mildronate, is a metabolic modulator presented as an injectable solution for intravenous use. It is employed to improve myocardial energy metabolism in adults with ischemic heart disease, angina pectoris, heart failure, cardiomyopathy, and peripheral arterial disease, helping to reduce ischemic injury.

GNH USA supplies Mildronate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global logistics.

Mildronate (meldonium dihydrate) is indicated for several cardiovascular conditions that involve myocardial ischemia.

- Ischemic heart disease: improves myocardial oxygen utilization and reduces anginal episodes. - Angina pectoris: decreases frequency and severity of chest pain during exertion. - Heart failure: supports cardiac output by enhancing metabolic efficiency. - Cardiomyopathy: mitigates myocardial stress and improves functional capacity. - Peripheral arterial disease: promotes tissue perfusion and reduces ischemic discomfort.

Mildronate may be associated with a range of adverse reactions, which are typically categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Headache: transient, often resolves without intervention. - Nausea: occasional, may improve with continued therapy. - Dizziness: mild, usually short‑lived. - Flushing: mild skin reddening. - Hypotension: mild blood pressure reduction.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure drop requiring medical attention. - Arrhythmia: irregular heart rhythm, potentially life‑threatening. - Anaphylactic reaction: rapid onset of swelling, rash, and breathing difficulty. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Severe allergic response: skin rash, itching, or angioedema. - Cardiogenic shock: rare but critical reduction in cardiac output.

When prescribing Mildronate, clinicians should consider several safety measures.

- Renal impairment: monitor renal function and adjust therapy as needed. - Cardiac patients: observe ECG and hemodynamic status during initiation. - Pregnancy: safety unknown; avoid unless benefits outweigh risks. - Breastfeeding: insufficient data; consider discontinuation. - Concomitant vasodilators: risk of additive hypotension, monitor blood pressure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mildronate can interact with other medicines; awareness of interaction severity helps guide therapy.

Major Interactions (Avoid): - Carnitine supplementation: may counteract metabolic effect. - Strong CYP450 inhibitors: potential increase in meldonium exposure. - Antihypertensive agents: additive blood pressure lowering.

Moderate Interactions (Monitor Closely): - Beta‑blockers: monitor heart rate and contractility. - Diuretics: watch electrolyte balance and volume status. - Anticoagulants: observe for altered bleeding risk.